Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-myeloablative Allo-HCT for Multiple Myeloma
NCT00185614Phase 2Completed
- Start
- Aug 2000
- Primary completion
- Apr 2009
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic hematopoietic stem cells in multiple myeloma (MM). Primary endpoint: Event-free Survival at 3 years. Started Aug 2000; status: completed.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00185614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00185614.